
This phase 3 study investigated lenabasum's efficacy and safety in diffuse cutaneous systemic sclerosis (dcSSc). Among 365 patients, lenabasum didn't meet the primary endpoint (CRISS) at week 52 compared to placebo. However, greater improvement in skin thickness and lung function was seen with lenabasum in those on mycophenolate or <1-year immunosuppressive therapy.
Like
Save
Share